期刊
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
卷 1482, 期 1, 页码 213-224出版社
WILEY
DOI: 10.1111/nyas.14508
关键词
esophageal squamous cell carcinoma; multidisciplinary treatment; neoadjuvant chemoradiotherapy; neoadjuvant chemotherapy; neoadjuvant immunotherapy
资金
- Program of Science and Technology of Sichuan Province [2018SZ0199]
- International Cooperation Projects of Science and Technology of Sichuan Province [2020YFH0169]
Esophageal squamous cell carcinoma (ESCC) is one of the most common malignancies worldwide, especially in East Asia. ESCC accounts for more than 90% of esophageal cancer. Currently, neoadjuvant therapy in combination with surgical resection is the mainstay of treatment. However, the overall survival rate of patients with locally advanced ESCC is not satisfactory even when treated following the standard treatment guidelines. With neoadjuvant chemoradiotherapy, chemotherapy, or emerging immunotherapy, continuous exploration of efficacy in relation to ESCC is expected to improve overall survival further. Here, we review and summarize current evidence for efficacy of preoperative therapy for locally advanced ESCC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据